Key result
The provided abstract contains only author affiliations and funding information, reporting no clinical data or findings for low-molecular-weight heparin therapy in children.
Answers are grounded in this paper and cite their sources.
Abstract reports no clinical data; leaves open evidence on LMWH use in children.
From the Thrombosis Service, The Hospital For Sick Children, and the Department of Pediatrics, University of Toronto, Toronto, Canada. Submitted for publication June 2, 2000; accepted November 30, 2000. Dr. Massicotte was supported by a Medical Research Council of Canada (MRC) and Pharmaceutical Manufacturers Association of Canada Scholarship (PMAC, Knoll Pharma BASF). This work was supported by an MRC/PMAC Grant and a Heart and Stroke Foundation of Ontario Grant. Address correspondence and reprint requests to Dr. Patricia Massicotte, The Hospital for Sick Children, Department of Pediatrics, Division of Hematology/Oncology, 555 University Avenue, M5G 1X8 Toronto, Ontario, Canada. E-mail: [email protected]
No takes yet. Share an insight, caveat, or question.
M. Patricia Massicotte (2001) studied this question. Low-Molecular-Weight Heparin was evaluated. The provided abstract contains only author affiliations and funding information, reporting no clinical data or findings for low-molecular-weight heparin therapy in children.
Synapse has enriched 10 related papers. Consider them for comparative context: